Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells by unknown
Maiolino et al. Journal of Nanobiotechnology  (2015) 13:29 
DOI 10.1186/s12951-015-0088-2RESEARCH Open AccessBiodegradable nanoparticles sequentially
decorated with Polyethyleneimine and Hyaluronan
for the targeted delivery of docetaxel to airway
cancer cells
Sara Maiolino1†, Annapina Russo2†, Valentina Pagliara2, Claudia Conte1, Francesca Ungaro1, Giulia Russo2*
and Fabiana Quaglia1*Abstract
Background: Novel polymeric nanoparticles (NPs) specifically designed for delivering chemotherapeutics in the
body and aimed at improving treatment activity and selectivity, cover a very relevant area in the field of
nanomedicine.
Here, we describe how to build a polymer shell of Hyaluronan (HA) and Polyethyleneimine (PEI) on biodegradable
NPs of poly(lactic-co-glycolic) acid (PLGA) through electrostatic interactions and to achieve NPs with unique
features of sustained delivery of a docetaxel (DTX) drug cargo as well as improved intracellular uptake.
Results: A stable PEI or HA/PEI shell could be obtained by careful selection of layering conditions. NPs with exquisite
stability in salt and protein-rich media, with size and surface charge matching biological requirements for intravenous
injection and endowed with sustained DTX release could be obtained. Cytotoxicity, uptake and activity of both PLGA/
PEI/HA and PLGA/PEI NPs were evaluated in CD44(+) (A549) and CD44(−) (Calu-3) lung cancer cells. In fact, PEI-coated
NPs can be formed after degradation/dissociation of the surface HA because of the excess hyaluronidases
overexpressed in tumour interstitium. There was no statistically significant cytotoxic effect of PLGA/PEI/HA and
PLGA/PEI NPs in both cell lines, thus suggesting that introduction of PEI in NP shell was not hampered by its
intrinsic toxicity. Intracellular trafficking of NPs fluorescently labeled with Rhodamine (RHO) (RHO-PLGA/PEI/HA and
RHO-PLGA/PEI NPs) demonstrated an increased time-dependent uptake only for RHO-PLGA/PEI/HA NPs in A549 cells as
compared to Calu-3 cells. As expected, RHO-PLGA/PEI NP uptake in A549 cells was comparable to that observed in
Calu-3 cells. RHO-PLGA/PEI/HA NPs internalized into A549 cells showed a preferential perinuclear localization. Cytotoxicity
data in A549 cells suggested that DTX delivered through PLGA/PEI/HA NPs exerted a more potent antiproliferative activity
than free DTX. Furthermore, DTX-PLGA/PEI NPs, as hypothetical result of hyaluronidase-mediated degradation in tumor
interstitium, were still able to improve the cytotoxic activity of free DTX.
Conclusions: Taken together, results lead us to hypothesize that biodegradable NPs coated with a PEI/HA shell represent
a very promising system to treat CD44 overexpressing lung cancer. In principle, this novel nanocarrier can be extended to
different single drugs and drug combinations taking advantage of the shell and core properties.
Keywords: Nanoparticles, CD44 targeting, Poly(lactic-co-glycolic) acid, Hyaluronan, Polyethyleneimine, Docetaxel, Lung
cancer* Correspondence: giulia.russo@unina.it; quaglia@unina.it
†Equal contributors
2Laboratory of Biochemistry, Department of Pharmacy, University of Napoli
Federico II, Via Domenico Montesano 49, Napoli 80131, Italy
1Laboratory of Drug Delivery, Department of Pharmacy, University of Napoli
Federico II, Via Domenico Montesano 49, Napoli 80131, Italy
© 2015 Maiolino et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Maiolino et al. Journal of Nanobiotechnology  (2015) 13:29 Page 2 of 13Background
In the past twenty years, nanotherapeutics have been in-
troduced in the clinical practice for treating tumors with
the goal to improve therapeutic outcome of conventional
pharmacological therapies, to alleviate their toxicity as
well as to overcome multidrug resistance [1-8]. By pro-
viding a protective housing for the drug, nanoscale de-
livery system can in theory offer the advantages of
drug protection from degradation, efficient control of
pharmacokinetics and accumulation in tumor tissue,
thus limiting drug interaction with healthy cells and as
a consequence side effects.
Polymer-based nanoparticles (NPs) specifically de-
signed for cancer treatment cover a very relevant and
widely explored area in the field of nanotechnology
[9-11]. The main advantages of polymeric NPs reside in
the opportunity to readily manipulate their properties by
selecting polymer type and mode of carrier preparation.
As a consequence, not only those surface features which
affect biological behavior (spatial distribution of drug
dose in the body) are controlled, but also timing of drug
release (temporal control of drug availability to target) is
predetermined.
Due to their well-established biocompatibility and
safety profile, nano-oncologicals made of polyesters such
as poly(lactic-co-glycolic) acid (PLGA) can be considered
one of the most interesting systems for this application
and are greatly emerging in the field [2]. To be used as
an effective nanomedicine, PLGA NPs need to be
surface-engineered according to specific technological
and therapeutic needs [12]. Core-shell architecture rep-
resents an effective way to attain multiple functionalities
on a nanoscopic length scale. Indeed, a core (template)
generally carrying a chemotherapeutic agent can be
surrounded by a shell with different composition and
configuration that provides a functional and interacting
interface with biological environment [13]. The shell is
also responsible of colloidal stability of the system “in
the bottle” (shelf life) and in biologically relevant
media. A wide array of currently-available materials
and possible combinations can be used to fabricate
core-shell NPs spanning from tailored amphiphilic
polymers, able to form nanoassemblies in aqueous
media, to nanostructures where electrostatic or hydropho-
bic interactions drive shell deposition on a core template
[9,11]. The latter approach is very attractive since no com-
plicate synthetic steps to attain polymer functionalization
are required.
In the construction of layered NPs, an emerging aspect
in nanotechnology is represented by the use of polymers
with specific functions for cancer treatment. Two rele-
vant examples are Polyethyleneimine (PEI) and Hyaluro-
nan (HA). PEI is a cationic polymer widely employed for
transfection due to its capacity to complex polyanionicDNA and oligonucleotides (decoy, siRNA, miRNA)[14].
Recently, it has been demonstrated that PEI can induce
anticancer effects via electrostatic interaction with cell
membranes [15,16]. Furthermore, it has been observed
that intratumoral injection of different cationic polymers
evokes a robust infiltration of Th 1 and NK cells into
the tumor site, reversing the tumor microenvironment
from immunosuppressive to immunostimulatory and in-
ducing massive tumor necrosis [17]. In other studies,
PEI triggered Antigen Presenting Cell activation via
TLR-signaling and exerted direct tumoricidal activity in
a mouse model of ovarian tumors [18]. Cationic NPs are
considered intriguing systems to promote deep penetra-
tion in tumor tissues [19,20]. Nevertheless, cationic NPs
induce rapid formation of complex aggregates with
negatively charged serum molecules or membranes of
cellular components, which are then cleared by the retic-
uloendothelial system (RES). More importantly, many
cationic nanosystems developed so far exhibit substantial
toxicity [21], which has limited their clinical applicability
thus demanding strategies to reversibly shield their sur-
face with biomimetic coatings.
A functional anionic polymer such as hyaluronan (HA)
can perfectly fit the purpose to cover cationic NPs through
electrostatic interactions and to form a bioresponsive shell.
HA is a negatively-charged polysaccharide with a relevant
role in cancer since its receptors (CD44, RHAMN) are
overexpressed on the surface of a broad variety of cancer
cells [22]. Recently, combination of chemotherapeutic
drugs with HA NPs for selective targeting of CD44-
overexpressed cancer cells has received increasing at-
tention to improve specificity of the drug and alleviate
side effects [23]. In fact, receptor-mediated endocytosis
of HA-decorated NPs facilitates drug transport inside
the cells and contributes to enhanced drug cytotoxicity
[24]. Nevertheless, HA is involved in extracellular
matrix remodeling of cancer tissues since HA degrad-
ation by interstitium hyaluronidases (Hyals) is a process
at basis of facilitated metastasis formation [23].
Although based only on electrostatic interactions,
core-shell PLGA NPs prepared by stepwise modification
through sequential layering of positive and negative
polymers such as alginate/chitosan, alginate/polylysine
and HA/polylysine [25], HA/polyarginine [26] as well as
HA/PEI [27] has been found successful to achieve physic-
ally stable NPs for the co-delivery of different drug
combinations.
In this paper, we describe how to build a polymer shell
on biodegradable PLGA NPs through PEI or PEI/HA
electrostatic interactions and achieve NPs with unique
features of sustained delivery of their docetaxel (DTX)
drug cargo and improved intracellular uptake. In fact,
several DTX polymeric nanoplatforms have been devel-
oped so far to improve drug activity and selectivity as
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a formulation study aimed at optimizing preparation
conditions of NPs, a powder for injection was obtained
and characterized for release properties and stability in
media with different ions and protein contents. PEI and
HA/PEI-decorated NPs were tested for trafficking and
activity in CD44(+) and CD44(−) lung cancer cells and
potential contribute of HA targeting was highlighted.
Results and discussion
To improve DTX activity and internalization in airway
cancer cells, we tried to engineer biodegradable PLGA
NPs with either a PEI coating able to confer a cationic
charge to the system or a PEI/HA shell endowed with
ability of CD44 receptor targeting. An anionic non end-
capped PLGA nanoparticle template entrapping the model
anticancer drug DTX was covered with a polycationicFigure 1 Structure and properties of NPs during layering procedure.
polydispersity (PI) and zeta potential of NPs during coating and after dispe
of three measurements obtained on three different NP batches ± SD. C) TElayer of PEI (25 kDa, branched). Further application of a
finishing layer of low molecular weight HA (<10 kDa) was
accomplished to allow CD44 receptor targeting. We first
developed a robust layering procedure to obtain NPs and
then characterized the system in biologically-relevant
media. Next, cytotoxicity and uptake of the unloaded NPs,
as well as activity of DTX-loaded NPs in CD44(+) and
CD44(−) lung cancer cells were assessed also considering
a possible HA shedding and generation of PEI-coated
NPs.
Layering procedure
Preparation of DTX-loaded PLGA/PEI/HA NPs is a multi-
step process comprising i) the preparation of a PLGA
core template; ii) the absorption of a positive PEI layer;
iii) the absorption of a negative bioresponsive layer of
HA (Figure 1A). DTX-PLGA NPs were prepared byA) Schematic representation of the double coating process. B) Size,
rsion of NPs freeze-dried with trehalose in water. Results are the mean
M micrographs of PLGA/PEI/HA NPs.
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nic F68 water solution. The size of unloaded PLGA NPs
was only slightly affected by PLGA concentration while the
surface was always negative (Additional file 1: Figure S1A).
Thus, a PLGA concentration of 5 mg/mL was selected for
all further experiments. After a washing step to eliminate
surface-adsorbed Pluronic F68, around 60% of NPs with
the original size/zeta potential were recovered. Then, a first
positive layer of PEI was adsorbed through electrostatic in-
teractions by incubating NPs with a PEI water solution.
The process of polymer film growth onto NP surface
can be severely altered by several experimental factors
and mainly by salt concentration in the medium [33].
PEI layering was thereby carried out both in water and
PBS 0.01 M at pH 7.4. However, only water allowed the
prompt re-dispersion of PLGA/PEI NP pellet without
aggregation. Thus, all the preparation steps were carried
out in water. The addition of 125 μL of a PEI water solu-
tion at increasing concentration (0.5, 1.0 and 1.5 mg/
mL) caused an inversion of zeta potential from negative
to positive values (Additional file 1: Figure S1B). Optimal
conditions for layering were found at 1 mg/mL since
only a slight increase of size and polydispersity index
(PI) was observed (Figure 1B). PLGA/PEI NPs were
further collected to eliminate un-adsorbed PEI and dis-
persed in water again. In the following step, PLGA/PEI
NPs were finished with a HA layer giving PLGA/PEI/
HA NPs, which displayed a slightly increased size and
negative zeta potential. Quantitative adsorption of HA
on NP surface was confirmed by evaluating the amount
of HA in the solution after collecting NPs (no free HA
was detected in the medium).
In developing translational NPs for intravenous route, it
is of key importance to produce a lyophilized NP powder
with a suitable shelf-life and with effective dispersion in
the diluting vehicles usually employed for administration.
While PLGA/PEI and PLGA/PEI/HA NPs freeze-dried as
such underwent extensive aggregation and could not beTable 1 Properties of DTX-loaded NPs before and after freeze
DTX-PLGA/PEI NPs DTX-PL
Trehalose/NP weight ratio -
Yield (% ± SD) 21.2 ± 0.8a
Mean DH (nm ± SD) 155 ± 9
b 1
Polydispersity index 0.10b
Zeta Potential (mV) +39.0b
DTX actual loading(mg per 100 mg) 0.95 ± 0.5
PEI actual loading(mg per 100 mg) 7.94 ± 2.1
HA actual loading(mg per 100 mg) - 1
aCalculated as ratio between total component weight and NP weight.
bAs prepared NPs before freeze-drying.
cAfter dispersion of freeze-dried powder in water.dispersed in water (data not shown) the addition of a
cryoprotectant such as trehalose gave a powder that,
after dispersion in water, restored the original NP size,
PI and zeta potential (Figure 1B).
Properties of DTX-loaded NPs
Overall properties of DTX-loaded PLGA/PEI and
PLGA/PEI/HA NPs are reported in Table 1. DTX en-
trapment in the PLGA core did not alter size, PI and
zeta potential also after the freeze-drying step. Around
50% of the initial PEI amount was retained on NP sur-
face whereas the absorption of HA was complete. The
yield of the production process was found to be around
20% (Table 1), which is in line with values reported for
layered NPs. It is worth of note that final NPs can be
loaded with amount of DTX in the PLGA core up to
4 mg/100 mg NPs without altering size and zeta poten-
tial (Additional file 1: Table S1). These results are in line
with those found for DTX entrapped in PLGA NPs pre-
pared by nanoprecipitation [34]. TEM analysis con-
firmed the spherical morphology and lack of aggregation
of the final formulation (Figure 1C).
A drawback with a layering procedure carried out in
water could be the occurrence of weaker interactions be-
tween negative and positive polymer chains and, as a
consequence, the formation of a loose and poorly stable
coating. On these bases, we tested the stability of DTX-
PLGA/PEI and DTX-PLGA/PEI/HA NPs in different
media by measuring size and zeta potential (Figure 2A).
Both types of NPs were stable in NaCl 0.9% or glucose
5% solution giving size and zeta potential values in line
with those found in water. To mimic more closely NP
behavior in cell culture experiments, stability was also
assessed in DMEM without or with FBS (FBS- and FBS+,
respectively). The results suggested that DTX-PLGA/PEI
NPs greatly increase their size presumably due to ex-
tensive protein adsorption while size increase of DTX-
PLGA/PEI/HA NPs was limited. Size growth in the-drying











2.2 ± 0.8 - 0.20 ± 0.03
Figure 2 Properties of DTX-PLGA/PEI and DTX-PLGA/PEI/HA
NPs freeze-dried with trehalose. A) Size and zeta potential in
different media. B) Release profile (37°C) of DTX from NPs dispersed
in DMEM FBS+. External dialysis medium was a PBS solution at
pH 7.4. Free DTX is reported as control. Results are the mean of
three experiments ± SD.
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gregation over time. Zeta potential of DTX-PLGA/PEI
NPs in cell culture media switched to values very close
to neutrality independently of the presence of proteins.
Release profile of DTX from both NPs type was evalu-
ated by dialysis using DMEM FBS+ as dispersing
medium and PBS at pH 7.4 as external medium (sink
conditions were set). DTX release from DTX-PLGA/PEIand DTX-PLGA/PEI/HA NPs was monitored for 72 h
and compared with that of free DTX (Figure 2B). The
transport of free DTX toward the external medium was
found to be incomplete in this experimental set-up due
to strong DTX-protein interaction inside the dyalisis bag
hampering DTX transport in the external medium. This
behavior is in agreement with previous data collected on
DTX solubilized in human plasma [35]. However, a slow
and sustained release of DTX from both DTX-PLGA/
PEI and DTX-PLGA/PEI/HA NPs as compared with free
DTX was found. The release rate observed for coated
NPs was similar thus suggesting that for an unionized
drug such as DTX, the presence of the polyelectrolyte
layer does not represent a further barrier to drug trans-
port from the PLGA core.Cytotoxicity of unloaded NPs
The cytotoxicity was evaluated on PLGA/PEI/HA and
PLGA/PEI NPs, taking into account that NP shedding
due to HA degradation can occur in a biological envi-
ronments. Indeed, several cancers produce elevated
levels of Hyals. A higher expression level of Hyals was
also found in metastatic tumors as compared to non-
metastatic [23]. In principle, cationic NPs can be formed
by dissociation of the surface HA because of the excess
Hyals in tumor interstitium.
The cytotoxicity was assessed by the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and
lactate dehydrogenase (LDH) release assays. The experi-
ments were performed in A549 and Calu-3 cells selected
as CD44(+) and CD44(−) cell lines, respectively [36]. Cells
were incubated with a wide range of NP concentrations
(from 0.1 mg to 2 mg) and tested upon 24 h and 72 h of
treatment.
Results from MTT assay in Figure 3A show that 24 h
after the treatment, A549 and Calu-3 cells retained
about 90% viability when treated with various concentra-
tions of PLGA/PEI/HA NPs as compared with control
(untreated cells set to 100%). At 24 h, the cytotoxicity
curve for PLGA/PEI NPs followed an almost similar pat-
tern (Figure 3B). The observed results were confirmed
by the values of cell mortality from LDH assay. A549
and Calu-3 cells were incubated with the same concen-
trations of PLGA/PEI/HA or PLGA/PEI NPs and cell
membrane damage was assessed 24 h later (Figure 3C
and D). As shown, the results obtained from the LDH
assay were in line with those obtained with the MTT
assay.
Data obtained from MTT and LDH assays after 72 h
of treatment with PLGA/PEI/HA and PLGA/PEI NPs
demonstrated no significant NP toxicity (Additional
file 1: Figure S2) analogously to PLGA NPs (Additional
file 1: Figure S3).
Figure 3 Cytotoxicity of unloaded NPs. A549 and Calu-3 cells were exposed to increasing concentrations of PLGA/PEI/HA and PLGA/PEI
NPs for 24 h. After incubation, cell viability and released LDH were evaluated using the MTT (A, B) and LDH (C, D) assays. The cell viability
and LDH release from untreated control were set to 100% and 0%, respectively. Results are presented as percentage (mean ± SEM) (n = 3) of
the control cells. Differences were considered not statistically significant (P >0.05).
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tistically significant cytotoxic effect (P >0.05) of both
PLGA/PEI/HA and PLGA/PEI NPs in either A549 or
Calu-3 cell lines and supported the hypothesis that PEI
strongly decreases its cytotoxicity when delivered
through NPs presumably due to a depression of cationic
charge in the medium [37,38].
Uptake of NPs
The natural turnover of free HA is predominantly based
on its CD44 receptor-mediated internalization in cells
[39]. Starting from this knowledge, we became interested
to study the intracellular uptake of PLGA/PEI/HA and
PLGA/PEI NPs in A549 (CD44(+)) and Calu-3
(CD44(−)) cells. To this aim, fluorescent NPs labeledwith Rhodamine (RHO), named RHO-PLGA/PEI/HA and
RHO-PLGA/PEI NPs, were prepared from a RHO-PLGA
covalent derivative (see Additional file 1: Figure S4). Prop-
erties of fluorescent RHO-NPs were comparable to those
of untagged NPs (see Additional file 1: Table S2). Next,
A549 and Calu-3 cells were incubated with RHO-PLGA/
PEI/HA and RHO-PLGA/PEI for 4 h and 24 h. The fluor-
escence intensity of the internalized RHO-NPs was mea-
sured by fluorimetry. As shown in Figure 4 A, in A549
cells the treatment with RHO-PLGA/PEI/HA NPs was as-
sociated to an increasing time-dependent cellular uptake
(30% and 80% after 4 h and 24 h, respectively). The obser-
vation that the lack of CD44 receptor did not provoke any
significant uptake of RHO-PLGA/PEI/HA NPs in Calu-3
cells confirmed that the uptake of HA-decorated NPs was
Figure 4 Cellular uptake of fluorescent NPs. Intracellular levels of
fluorescent RHO-PLGA/PEI and RHO-PLGA/PEI/HA NPs. A549 and
Calu-3 cells were incubated with 0.5 mg/ml of RHO-PLGA/PEI/HA
NPs (A) and RHO-PLGA/PEI NPs (B) for 4 h and 24 h. All measurements
were normalized to the fluorescence of RHO-labeled NPs in cell
medium set as 100%. Results are presented as percentage (mean
± SEM) (n = 3) of the control cells.
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endocytosis mechanism of PLGA/PEI/HA NPs internaliza-
tion depends on the presence of HA onto the surface. As
expected, RHO-PLGA/PEI NP uptake in A549 cells was
comparable to that observed in Calu-3 cells (Figure 4B).
However, it is important to note that RHO-PLGA/PEI NPs
were still able to penetrate into cancer cells, giving about
10% and 35% NP uptake after 4 h and 24 h of treatment,
respectively (Figure 4B). This finding is very intriguing in
the light of recent data demonstrating that in tumor micro-
environment HA-coated NPs could be converted to un-
coated NPs as results of Hyals-mediated degradation [20].
In perspective, loss of HA coating can allow in situ gener-
ation of cationic NPs, which are still able to effectively
enter inside cancer cells.
Next, to investigate the subcellular distribution of in-
ternalized NPs, we carried out confocal laser scanner
microscopy (CLSM) analysis into A549 cells (Figure 5
and Additional file 1: Figure S5). After incubation withRHO-PLGA/PEI/HA NPs (Figure 5A) and RHO-PLGA/
PEI NPs (Figure 5E), the cells were stained with DAPI
(Figure 5B and F) and observed under the microscope.
A large majority of the RHO-PLGA/PEI/HA NPs-
associated fluorescence appeared to be distributed in the
vicinity, and surrounding, of the cells nuclei, confirming
the internalization of NPs (Figure 5C). The x-axis projec-
tions are shown in Figure 5D. Analysis of z-sections taken
through the cell nucleus showed the absence of any fluor-
escent signal for both types of NPs (see Additional file 1:
Figure S6). It may be noticed that the perinuclear accumu-
lation of NPs after internalization in cells can provide a
sustained drug delivery in the proximity of the nucleus.
This feature might be interesting for the development of
tumor suppressor gene-loaded NPs as apoptosis-induction
adjuvant, aimed at improving the outcome of common an-
ticancer therapies as 5-FU and L-OHP [40]. Internalized
RHO-PLGA/PEI NPs (Figure 5G and H) were indeed
more homogeneously distributed in the whole cytoplasm.
The quantification of intracellular fluorescence demon-
strated the efficacy of HA to mediate RHO-PLGA/PEI/
HA NP internalization (about 80%) as compared to non-
targeted RHO-PLGA/PEI NPs (about 30%).
In addition to internalization mechanisms, the intracel-
lular trafficking of NPs within the cell are critical elements
to study when a new drug carrier is proposed. Among
these issues, the subcellular distribution of the NPs repre-
sents an important aspect of NP dynamics. Lysosomes are
a common terminal degradative compartment of certain
endocytotic pathways. Thus, understanding whether NPs
are delivered to the lysosomes following their internaliza-
tion is a key point [28]. To determine whether the inter-
nalized RHO-PLGA/PEI/HA NPs were addressed to the
lysosomal compartments, A549 cells were incubated with
fluorescent RHO-PLGA/PEI/HA NPs for 24 h (Figure 6A)
and then stained with LysoTracker Green (Figure 6B) and
DAPI (Figure 6C). As shown in Figure 6D, a partial colo-
calization of RHO-PLGA/PEI/HA NPs with lysosome, as
evident from the appearance of orange to yellow fluores-
cence, was observed. The x-axis projection was also shown
(Figure 6E). This finding suggests that both different entry
mechanisms of NPs and a possible NP escape from lyso-
somes can contribute to their intracellular distribution,
which needs to be addressed in further studies.
Cytotoxicity of DTX-loaded NPs
Once the biological behavior of NPs was characterized,
we tested their ability to improve the activity of DTX. In
vitro cytotoxicity of DTX-PLGA/PEI/HA and DTX-
PLGA/PEI NPs was evaluated in A549 cells after 24 h
and 72 h exposure by using MTT and LDH assays and
compared to that of free DTX. Extrapolation of the dose
causing 50% cell death (IC50) from the dose–response
curve at 72 h (Table 2) showed that in A549 cells treated
Figure 5 Confocal microscopy images of A549 cells after incubation with fluorescent NPs. A549 cells were incubated with RHO-PLGA/PEI/
HA NPs (A) and RHO-PLGA/PEI NPs (E) for 24 h. Confocal microscopy images 100X: A549 cell nuclei stained with DAPI (B, F). Merge of the same
field for composite images (C, G), scale bar = 10 μm. Pictures were processed using ImageJ Software to reconstruct the x-axis projection using
stack images (D, H). Quantification of fluorescence intensity is shown. Bars represent mean values ± SEM of experiments done in
triplicate. *P < 0.05.
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higher than that of free DTX. Nevertheless, an activity
similar to that of free DTX was found in Calu3 cells.DTX-PLGA/PEI NPs displayed an activity comparable
to that of free DTX in both cell lines, although frac-
tional drug release occurred. The observed results were
Figure 6 Subcellular distribution of fluorescent NPs in A549 cells. A549 cells were incubated with RHO-PLGA/PEI/HA NPs for 24 h. Confocal
microscopy images 100X: RHO-PLGA/PEI/HA NPs (A), lysosomes of A549 cells stained with LysoTracker Green (B), A549 cell nuclei stained with
DAPI (C). Merge of the same field for composite images (D), scale bar = 10 μm. Pictures were processed using ImageJ Software to reconstruct the
x-axis projection using stack images (E). Composite image demonstrated colocalization of RHO-PLGA/PEI/HA NPs with lysosomes.
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Results from MTT and LDH assays of DTX-PLGA/PEI
NPs at 72 h (Figure 7B and D) showed that the cytotox-
icity induced by DTX-PLGA/PEI NPs was increased of
about 15% as compared with free DTX. Data from
MTTand LDH assays at 24 h (Additional file 1: Figure S7)
show a similar trend.
The increase of DTX activity when delivered from NPs
can be explained on the basis of its influx/efflux from
cells as well as its mode of action. Concerning influx/ef-
flux, although the exact mechanism of DTX entry inside
cells (passive diffusion, active transporters, free DTX,
protein-bound) is not clear, it has been demonstrated
that effective uptake of NPs can well correlate with DTX
activity. After NP entry, DTX is released, binds tubulin
and stabilizes microtubules, leading to cell cycle arrest atTable 2 IC50 values of free DTX, DTX-PLGA/PEI and
DTX-PLGA/PEI/HA NPs on A549 cells following 24 and
72 h incubation (n = 3)
IC50 (μg/mL)
DTX DTX-PLGA/PEI NPs DTX-PLGA/PEI/HA NPs
24 h 0.5 ± 0.048 0.48 ± 0.089 0.3 ± 0.030
72 h 0.1 ± 0.062 0.07 ± 0.072 0.05 ± 0.040G2M phase and further to initiation of apoptosis and
cytotoxicity [41], It is possible that slow intracellular re-
lease of DTX from NPs is much more controlled than a
single extracellular dose where above a certain DTX
level, a saturation of binding site for tubulin occurs and
drug efflux start taking place [42]. Furthermore, efflux of
DTX can be hampered by NPs, which is in line with
reversion of multi Drug resistance observed in vitro and
in vivo when employing DTX nanoformulations [43].
Taken together, results lead us to hypothesize that
once the DTX-PLGA/PEI/HA NPs reach the CD44-
overexpressed tumor site, they could be uptaken through
CD44 receptor, be distributed to different critical com-
partments where more efficient drug release as com-
pared with the free DTX form is achieved. Nevertheless,
DTX-PLGA/PEI NPs, as hypothetical result of Hyals-
mediated degradation in tumor [20] are still able to im-
prove the cytotoxic activity of free DTX contributing in
this way to further increase the therapeutical potential of
original DTX-PLGA/PEI/HA NPs.
Conclusion
This study has demonstrated that it is possible to build
CD44-targeted NPs with sustained drug delivery by elec-
trostatic assembly of proper polymer building blocks.
HA-coated NPs with excellent stability in complex
Figure 7 Cytotoxicity of DTX loaded-NPs in A549 cells. A549 cells were exposed to increasing concentrations of free DTX, DTX-PLGA/PEI/HA
NPs or DTX-PLGA/PEI NPs for 72 h. After incubation, cell viability and released LDH were evaluated using the MTT (A, B) and LDH (C, D) assays.
The cell viability and LDH release from untreated cells were set to 100% and 0%, respectively. Results are presented as percentage (mean ± SEM)
(n = 3) of the control cells. *P <0.05, #P < 0.001.
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and activity in CD44-overexpressing lung cancer
cells as compared with free drug were obtained.
Cationic NPs as such, or generated after possible
HA shedding in tumor interstium, displayed a
higher cytotoxicity than that of free drug, further
highlighting the therapeutic potential of the whole
nanocarrier. Taken together, results lead us to
hypothesize that biodegradable NPs developed here
represent a very promising system for the targeted
delivery of different single drugs and drug combina-
tions taking advantage of the shell and core
properties.Methods
Materials
Docetaxel (DTX, MW= 807.88) was purchased from LC
laboratories (USA). Hyaluronan (HA, <10 kDa) was a kind
gift of Magaldi Life S.r.l. (Italy). Poly(lactic-co-glycolic) acid
(PLGA) (D,L-lactic, 50:50 Resomer RG 502H, inherent vis-
cosity 0.16 - 0.24 dl/g) was purchased from Boehringer
Ingelheim (Germany). Rhodamine B (RHO), trehalose,
polyethyleneimine (PEI, 25 kDa branched), copper (II) sul-
fate, hexadecyltrimethyl-ammonium bromide, poloxamer
188 (Pluronic® F68), sodium acetate, sodium chloride, so-
dium hydroxide, glacial acetic acid and trifluoracetic acid
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and acetone were purchased from Carlo Erba Reagenti
(Italy). DMEM and Fetal Bovine Serum (FBS) were pur-
chased from GibcoLife Technologies. Distilled water was
used throughout the study.
Preparation of DTX-PLGA/PEI/HA NPs
NPs were prepared through a layer-by-layer deposition
method. In a first step, DTX-PLGA NPs were prepared
by nanoprecipitation. PLGA 502H (5 mg) and DTX (5%
w/w ) were co-dissolved in acetone (1 mL) and added
drop-wise to 2 mL of an aqueous phase containing
Pluronic F68 (0.1% w/v) under magnetic stirring. The or-
ganic solvent was then evaporated under vacuum using
a rotary evaporator for 15 min. Thereafter, NP disper-
sion was splitted in 4 Eppendorf® tubes and centrifuged
at 5000 x g for 15 min (Mikro 20 Zentrifugen). In the
second step, NP pellet in each Eppendorf® tube was dis-
perded in 1 mL of ultrapure water (final PLGA NP con-
centration was 1.5 mg/mL) and in each sample 125 μL
of a PEI solution in water (0.5, 1.0 and 1.5 mg/mL) were
added under stirring for 15 min. Thereafter, each sample
was centrifuged again (2.800 x g for 10 min) to eliminate
unadsorbed PEI and redispersed in 1 mL of ultrapure
water (DTX-PLGA/PEI). In the third step, 100 μL of a
HA solution (1 mg/mL) were added to PLGA/PEI NPs
under stirring for 15 min (DTX-PLGA/PEI/HA). Final
NPs were freeze-dried for 24 h with trehalose as cryopro-
tectant (30 mg in each vial) and kept at 4°C. Recovery yield
of production process was evaluated on an aliquot of
DTX-PLGA/PEI/HA NPs (without cryoprotectant) by
weighting the solid residue after freeze-drying. Results are
expressed as the ratio of the actual NPs weight to the the-
oretical polymer weight × 100.
Fluorescent NPs were prepared analogously by incorp-
orating a 20% w/w of PLGA-RHO (see supplementary
material S2) to PLGA when forming the core.
Characterization of DTX-loaded NPs
Size, surface charge and morphology
Hydrodynamic diameter, polydispersity index (PI) and
Zeta potential of NPs after each preparation step were
determined on a Zetasizer Nano Z (Malvern Instruments
Ltd., UK). Results are reported as mean of three separate
measurements on three different batches ± SD.
Particle morphology was analyzed on a NP dispersion
in water (1 mg/mL) by Transmission Electron Micros-
copy (TEM) (CM 12 Philips, The Netherlands)
DTX entrapment efficiency
DTX loading inside DTX-PLGA/PEI/HA NPs was
assessed by placing 0.5 mg of freeze-dried NPs or
30.5 mg of NPs freeze-dried with trehalose in 500 μL of
DCM under stirring. The sample was dried and then500 μL of water and 500 μL of acetonitrile were added
under stirring. The sample was finally filtered through a
0.45 μm filter (RC, Chemtek, Italy).
DTX was analyzed by HPLC on an apparatus
equipped with a LC-10ADvp pump, a SIL-10ADvp
autoinjector, a SPD-10Avp UV–Vis detector and a C-
R6 integrator (Shimadzu, Japan). The analysis was per-
formed on a Supelco 5 μm, C18 column (250 × 4.6 mm,
Å). The mobile phase was a 55:45 (v/v) mixture of water
with TFA 0.1% and acetonitrile pumped at a flow rate of
1 mL/min. The UV detector was set at 227 nm. A calibra-
tion curve for DTX in ethanol was constructed in the con-
centration range 0.980–196 μg/mL. The limits of
quantification (LOQ) and detection (LOD) were 1.29 and
0.39 μg/mL, respectively.PEI amount in NPs
PEI was quantified by a colorimetric method developed
previously [44]. To evaluate the amount of PEI in DTX-
PLGA/PEI/HA NPs, 0.5 mg of freeze-dried NPs (with
and without 30 mg of cryoprotectant) were treated with
1 mL of NaOH 1 M and stirred overnight. The sample
(0.5 mL) was diluted with 0.5 mL of 1 M acetic acid.
The resulting solution (0.5 mL) was added to 1 mL of
acetate buffer 0.1 M at pH 5.4, and complexed with
0.25 mL of a copper (II) sulfate water solution (0.1% w/
v). The absorbance value of each solution was recorded
at 281 nm (UV 1800, Shimadzu, Japan). A calibration
curve was constructed in the same condition in the PEI
concentration range 15–380 μg/mL.HA amount in NPs
To evaluate the extent of HA adsorption onto DTX-
PLGA/PEI/HA NPs, 0.5 mg of NPs were centrifuged at
13000 x g for 15 min, the supernatant was withdrawn
and freeze-dried. The solid residue was then dissolved
in 1 mL of 0.2 M acetate buffer (0.2 M sodium acetate
and 0.15 M sodium chloride) at pH 6. Thereafter,
2 mL of cetyltrimethylammonium bromide reagent
(2 g sodium hydroxide, 1 g hexadecyltrimethylammo-
nium bromide in 100 mL water) were added and the
sample was analyzed at 350 nm. A calibration curve
was constructed in the HA concentration range 10–
200 μg/mL.Stability in different media
Freeze-dried DTX-PLGA/PEI and DTX-PLGA/PEI/HA
NP powder (30.5 mg corresponding to 0.5 mg of NPs)
were dispersed in glucose 5%, NaCl 0.9%, DMEM with-
out and with FBS 10% (1 mL). Size, polydispersity index
and zeta potential of the samples were evaluated.
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In vitro release of DTX from NPs was assessed in
10 mM phosphate buffer containing NaCl (137 mM)
and KCl (2.7 mM) at pH 7.4 (PBS) by dialysis. Around
100 mg of DTX-PLGA/PEI and DTX-PLGA/PEI/HA
freeze-dried powder (corresponding to 2 mg of NPs)
were dispersed in 0.5 mL of DMEM with 10% FBS and
placed in a dialysis bag (MWCO= 3500 Da, Spectra/
Por®). The sample was plunged in PBS and kept at 37°C
up to 72 h. At selected time intervals, 1 mL of release
medium was withdrawn and replaced with an equal vol-
ume of fresh medium. DTX quantitative analysis was
performed as described above. Release profile of free
DTX dissolved in EtOH (10 μL, 2 μg/μL) and added to
0.5 mL of medium was assessed for comparison. Results
are expressed as % release over time ± SD of three
experiments.
Cell cultures and treatments
A549 and Calu-3 cell lines were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum (FBS) (Invitrogen,
Life Technologies, Italy), 1.5 mM L-glutamine, 100 units/
mL penicillin, and 100 μg/mL streptomycin under hu-
midified atmosphere of 5% CO2 at 37°C. Treatments of
cells were performed replacing the culture medium with
those containing increasing concentrations of DTX (0.001
- 0.5 μg/mL), unloaded and DTX-loaded PLGA/PEI and
PLGA/PEI/HA NPs (0.1 – 2 mg/mL of NPs). DMSO 0.1%
(v/v) was used as vehicle for DTX.
MTT assay
A549 and Calu-3 cells were seeded onto 96-well plates
(2 × 104 cells/well) and incubated with NPs for 24 h and
72 h. Then, cell viability was evaluated as mitochondrial
activity using the MTT [45]. The absorbance was mea-
sured at 540 nm using a microplate reader (Labsystems
Multiskan).
LDH assay
LDH leakage into the media, an indicator of cell injury,
was detected using the cytotoxicity assay, CytoTox 96®
(Promega, USA), according to the manufacturer’s in-
structions, as described [46]. Samples from clarified
medium of treated and untreated A549 and Calu-3 cells
were taken after 24 h and 72 h of incubation and the
LDH activity was measured.
Confocal microscopy
A549 cells and Calu-3 cells were plated on coverslips at
a density of 2 × 104 cells per well in 12-well plates as
previously reported [46]. Images of fluorescence-labeled
cells were captured with a Zeiss LSM 510 meta confocalmicroscope equipped with an oil immersion plan Apo-
chromat 100× objective 1.4 NA.
The laser line was set at 553 nm for RHO and 405 nm
for DAPI. Images were acquired simultaneously in red
and blue channels, and as z-stack. A gallery of optical
slices was collected and xz, yz composites were proc-
essed using ImageJ Software to reconstruct the x-axis
projection using stack images. The scale bars on all the
images correspond to 10 μm.
The uptake of NPs was evaluated by measuring the in-
corporation of the fluorescent probe RHO in A549 and
Calu-3 cells. Briefly, cells (2 × 104 cells per well in 12-well
plates) were collected and analysed by fluorimetry. The
fluorescence was measured with a Cary Eclipse fluores-
cence spectrophotometer (Varian). Excitation and emis-
sion wavelengths were 553 and 627 nm, respectively.
Statistical analysis
Error bars represent mean ± SEM from n = 3 biological
replicates. Statistical comparisons were made by one-way
ANOVA followed by Bonferroni’s test for multiple com-
parisons. *P <0.05 was considered significant, #P <0.001
was considered highly significant. P >0.05 was considered
not statistically significant.
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